3 hours ago
1
RomanBabakin/iStock Editorial via Getty Images
- The U.S. FDA will conduct an expedited review for an sBLA for Sanofi's (NASDAQ:SNY) Tzield as a potential treatment to delay the progression of stage 3 type 1 diabetes under the new National Priority Voucher pilot program. It is already
English (US) ·